Literature DB >> 17961967

[Treatment of a septic shock due to multiresistant Acinetobacter baumannii with tigecycline in combination].

T Leclerc1, J-P Perez, B Debien, P Clapson, B Lenoir.   

Abstract

We report a case of pulmonary and bloodstream infection due to multiresistant Acinetobacter baumannii six days after a severe trauma. Clinical condition transiently improved following antimicrobial treatment with ticarcillin-clavulanate and rifampicin. However, a septic shock developed on the fourth day due to the emergence of a strain only sensible to cotrimoxazole, colistin and tigecycline. Cure was achieved after a two week treatment with piperacillin-tazobactam, cotrimoxazole and tigecycline. This case shows that combined antimicrobial therapy including tigecycline can be relevant in some severe pulmonary infections due to multiresistant A. baumannii.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17961967     DOI: 10.1016/j.annfar.2007.08.015

Source DB:  PubMed          Journal:  Ann Fr Anesth Reanim        ISSN: 0750-7658


  4 in total

1.  Systematic review of invasive Acinetobacter infections in children.

Authors:  Jia Hu; Joan L Robinson
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

2.  Tigecycline combination for ventilator-associated pneumonia caused by extensive drug-resistant Acinetobacter baumannii.

Authors:  Hangyong He; Yali Zheng; Bing Sun; Xiao Tang; Rui Wang; Zhaohui Tong
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

Review 3.  Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence.

Authors:  Drosos E Karageorgopoulos; Theodore Kelesidis; Iosif Kelesidis; Matthew E Falagas
Journal:  J Antimicrob Chemother       Date:  2008-04-24       Impact factor: 5.790

4.  In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii.

Authors:  Luigi Principe; Silvia D'Arezzo; Alessandro Capone; Nicola Petrosillo; Paolo Visca
Journal:  Ann Clin Microbiol Antimicrob       Date:  2009-05-21       Impact factor: 3.944

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.